Zhejiang Medicine Beheer

Beheer criteriumcontroles 3/4

De CEO Zhejiang Medicine is Chun Lei Lu, benoemd in Jun2018, heeft een ambtstermijn van 6.42 jaar. bezit rechtstreeks 0.035% van de aandelen van het bedrijf, ter waarde CN¥ 5.39M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.4 jaar en 3.4 jaar.

Belangrijke informatie

Chun Lei Lu

Algemeen directeur

CN¥2.8m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	6.4yrs
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	3.4yrs
Gemiddelde ambtstermijn bestuur	3.4yrs

Recente managementupdates

Recent updates

CEO

Chun Lei Lu (57 yo)

6.4yrs

Tenure

CN¥2,844,200

Compensatie

Mr. Chun Lei Lu is President and Director of Zhejiang Medicine Co., Ltd. since June 15, 2018. He serves as Vice Chairman of Zhejiang Medicine Co., Ltd.since June 16, 2021. Mr. Lu was Executive Vice Presid...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Chun Lei Lu	President & Vice Chairman	6.4yrs	CN¥2.84m	0.035% CN¥ 5.4m
Hongwei Wang	Executive Vice President	6.4yrs	CN¥2.61m	0.019% CN¥ 3.0m
Huan Ming Yu	Vice President	9.4yrs	CN¥2.05m	0.042% CN¥ 6.3m
Jianhong Ping	Vice President	3.4yrs	CN¥1.90m	0.0052% CN¥ 793.1k
Yongbin An	Senior Manager	3.4yrs	CN¥2.24m	geen gegevens
Liping Liang	Senior Manager	3.4yrs	CN¥1.97m	0.0078% CN¥ 1.2m
Xiaoping Wang	Senior Manager	3.4yrs	CN¥2.10m	0.0052% CN¥ 793.1k
Nan Xing Li	Vice Chairman & Vice President	6.4yrs	CN¥2.86m	0.12% CN¥ 17.7m
Qirong Li	CFO & Financial Director	3.4yrs	CN¥1.22m	0.0052% CN¥ 793.1k
Guangshan Guo	Accounting Supervisor	no data	geen gegevens	geen gegevens
Minzhi Shao	Board Secretary	1.2yrs	geen gegevens	geen gegevens
Jin Lin Zhu	Vice President	9.4yrs	CN¥1.82m	0.036% CN¥ 5.6m

3.4yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 600216 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Chun Lei Lu	President & Vice Chairman	12.4yrs	CN¥2.84m	0.035% CN¥ 5.4m
Nan Xing Li	Vice Chairman & Vice President	6.4yrs	CN¥2.86m	0.12% CN¥ 17.7m
Chun Bo Li	Chairman of the Board	21.4yrs	CN¥3.46m	0.0097% CN¥ 1.5m
Naiwei Chen	Independent Director	6.4yrs	CN¥120.00k	geen gegevens
Yizheng Qiu	Independent Director	3.4yrs	CN¥120.00k	geen gegevens
Zhenhua Chu	Director	3.4yrs	CN¥1.86m	0.0078% CN¥ 1.2m
Yuqing Yu	Director	3.4yrs	CN¥1.85m	0.0052% CN¥ 793.1k
Qing Xia	Independent Director	3.4yrs	CN¥120.00k	geen gegevens
Xiaoming Wu	Independent Director	2.9yrs	CN¥120.00k	geen gegevens
Zhong Liu	Vice Chairman	1.4yrs	geen gegevens	geen gegevens
Yiyuan Wu	Chief Supervisor	1.4yrs	geen gegevens	geen gegevens
Hongyu Cang	Director	1.4yrs	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

48.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 600216 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Zhejiang Medicine Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Zhejiang Medicine Co., Ltd., Annual General Meeting, Jun 18, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.55 (vs CN¥0.029 in 3Q 2023)

Investor sentiment improves as stock rises 20%

Zhejiang Medicine Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.16 in 2Q 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Dividend reduced to CN¥0.15

Zhejiang Medicine Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Zhejiang Medicine Co., Ltd., Annual General Meeting, Jun 18, 2024

First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 1Q 2023)

Zhejiang Medicine Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment improves as stock rises 18%

Zhejiang Medicine Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.029 (vs CN¥0.10 in 3Q 2022)

Zhejiang Medicine Co., Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 2Q 2022)

Zhejiang Medicine Co., Ltd. to Report First Half, 2023 Results on Aug 24, 2023

First quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.27 in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.25 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.25 in 2Q 2021)

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.20 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.30 in 2Q 2020)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.75 (vs CN¥0.36 in FY 2019)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day high: CN¥15.25

New 90-day low: CN¥12.75

New 90-day low: CN¥13.19

Third quarter earnings released

Third quarter earnings released

New 90-day low: CN¥14.55

Zhejiang Medicine Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020

New 90-day low: CN¥15.44

New 90-day low - CN¥16.73

First half earnings released

Earnings released

Zhejiang Medicine Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd